Efficacy of decitabine combined with HAA regimen in treatment of children with leukemia
WANG Jing
QIU Zhen
WANG Liang
Abstract：Objective:To study the efficacy and safety of dexamethasone(DAC)combined with homoharringtonine(HHT),cytarabine(Ara-C),and clarithromycin chemotherapy(ACR)(HAA regimen)in treatment of refractory/relapsed acute myeloid leukemia(R/R AML)in children.Methods:A combination of HAA and DAC regimen was used to treat 46 children aged 1-14 with R/R AML.Among them,30 children were diagnosed to suffer from relapsed AML and 16 children were diagnosed to suffer from refractory AML.Retrospective analysis of the effectiveness and safety of the plan was conducted.Results:A total of 32 children(69.5%)achieved complete remission(CR)after the first course of induction therapy,and 5 children(10.8%)achieved partial remission(PR),with a total effective rate of 80.3%.Gender,age,and disease status had no significant impact on the remission rate.A total of 28 children(60.8%)experienced grade 4 bone marrow suppression,32 children(69.5%)experienced varying degrees of infection,including 20 cases of pneumonia(43.5%),and 5 children experienced reversible liver function abnormalities during chemotherapy.There were no patients with heart or kidney function damage.Conclusion:The combination of DAC and HAA regimen has a high remission rate and good safety in the treatment of refractory and recurrent AML in children,and can be considered as a pre hematopoietic stem cell transplantation bridging regimen.
Keywords：Acute myeloid leukemiaRelapsesRefractoryHAADesitabineChildren
Publication Date：2023-10-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 352-355 )